205 related articles for article (PubMed ID: 22120988)
1. Methamphetamine self-administration acutely decreases monoaminergic transporter function.
McFadden LM; Stout KA; Vieira-Brock PL; Allen SC; Nielsen SM; Wilkins DG; Hanson GR; Fleckenstein AE
Synapse; 2012 Mar; 66(3):240-5. PubMed ID: 22120988
[TBL] [Abstract][Full Text] [Related]
2. Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure.
McFadden LM; Hadlock GC; Allen SC; Vieira-Brock PL; Stout KA; Ellis JD; Hoonakker AJ; Andrenyak DM; Nielsen SM; Wilkins DG; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2012 Feb; 340(2):295-303. PubMed ID: 22034657
[TBL] [Abstract][Full Text] [Related]
3. Alterations in the striatal dopamine system during intravenous methamphetamine exposure: effects of contingent and noncontingent administration.
Laćan G; Hadamitzky M; Kuczenski R; Melega WP
Synapse; 2013 Aug; 67(8):476-88. PubMed ID: 23417852
[TBL] [Abstract][Full Text] [Related]
4. Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure.
McFadden LM; Vieira-Brock PL; Hanson GR; Fleckenstein AE
Neuropharmacology; 2015 Jun; 93():146-54. PubMed ID: 25645392
[TBL] [Abstract][Full Text] [Related]
5. Amphetamine and methamphetamine reduce striatal dopamine transporter function without concurrent dopamine transporter relocalization.
German CL; Hanson GR; Fleckenstein AE
J Neurochem; 2012 Oct; 123(2):288-97. PubMed ID: 22804716
[TBL] [Abstract][Full Text] [Related]
6. Neuronal dopamine transporter activity, density and methamphetamine inhibition are differentially altered in the nucleus accumbens and striatum with no changes in glycosylation in rats behaviorally sensitized to methamphetamine.
Bjorklund NL; Sorg BA; Schenk JO
Synapse; 2008 Oct; 62(10):736-45. PubMed ID: 18651643
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of estradiol on the reduction of striatal dopamine by amphetamine in ovariectomized rats.
Yu PL; Wu CI; Lee TS; Pan WH; Wang PS; Wang SW
J Cell Biochem; 2009 Dec; 108(6):1318-24. PubMed ID: 19830701
[TBL] [Abstract][Full Text] [Related]
8. Lobeline effects on tonic and methamphetamine-induced dopamine release.
Wilhelm CJ; Johnson RA; Eshleman AJ; Janowsky A
Biochem Pharmacol; 2008 Mar; 75(6):1411-5. PubMed ID: 18191815
[TBL] [Abstract][Full Text] [Related]
9. Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity.
Volz TJ; Farnsworth SJ; Rowley SD; Hanson GR; Fleckenstein AE
Synapse; 2009 Feb; 63(2):147-51. PubMed ID: 19021208
[TBL] [Abstract][Full Text] [Related]
10. Psychoactive substrates stimulate dopamine transporter phosphorylation and down-regulation by cocaine-sensitive and protein kinase C-dependent mechanisms.
Cervinski MA; Foster JD; Vaughan RA
J Biol Chem; 2005 Dec; 280(49):40442-9. PubMed ID: 16204245
[TBL] [Abstract][Full Text] [Related]
11. Amphetamine and methamphetamine differentially affect dopamine transporters in vitro and in vivo.
Goodwin JS; Larson GA; Swant J; Sen N; Javitch JA; Zahniser NR; De Felice LJ; Khoshbouei H
J Biol Chem; 2009 Jan; 284(5):2978-2989. PubMed ID: 19047053
[TBL] [Abstract][Full Text] [Related]
12. Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum.
Eyerman DJ; Yamamoto BK
J Pharmacol Exp Ther; 2005 Jan; 312(1):160-9. PubMed ID: 15331654
[TBL] [Abstract][Full Text] [Related]
13. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.
Hansen JP; Riddle EL; Sandoval V; Brown JM; Gibb JW; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2002 Mar; 300(3):1093-100. PubMed ID: 11861820
[TBL] [Abstract][Full Text] [Related]
14. Methamphetamine self-administration is associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat.
Krasnova IN; Justinova Z; Ladenheim B; Jayanthi S; McCoy MT; Barnes C; Warner JE; Goldberg SR; Cadet JL
PLoS One; 2010 Jan; 5(1):e8790. PubMed ID: 20098750
[TBL] [Abstract][Full Text] [Related]
15. Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.
Nickell JR; Krishnamurthy S; Norrholm S; Deaciuc G; Siripurapu KB; Zheng G; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2010 Feb; 332(2):612-21. PubMed ID: 19855096
[TBL] [Abstract][Full Text] [Related]
16. Repeated administration of D-amphetamine induces loss of [123I]FP-CIT binding to striatal dopamine transporters in rat brain: a validation study.
Booij J; de Bruin K; Gunning WB
Nucl Med Biol; 2006 Apr; 33(3):409-11. PubMed ID: 16631090
[TBL] [Abstract][Full Text] [Related]
17. Extended access to methamphetamine self-administration up-regulates dopamine transporter levels 72 hours after withdrawal in rats.
D'Arcy C; Luevano JE; Miranda-Arango M; Pipkin JA; Jackson JA; Castañeda E; Gosselink KL; O'Dell LE
Behav Brain Res; 2016 Jan; 296():125-128. PubMed ID: 26367473
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain.
Freyberg Z; Sonders MS; Aguilar JI; Hiranita T; Karam CS; Flores J; Pizzo AB; Zhang Y; Farino ZJ; Chen A; Martin CA; Kopajtic TA; Fei H; Hu G; Lin YY; Mosharov EV; McCabe BD; Freyberg R; Wimalasena K; Hsin LW; Sames D; Krantz DE; Katz JL; Sulzer D; Javitch JA
Nat Commun; 2016 Feb; 7():10652. PubMed ID: 26879809
[TBL] [Abstract][Full Text] [Related]
19. Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation.
Hadlock GC; Chu PW; Walters ET; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2010 Oct; 335(1):207-12. PubMed ID: 20622144
[TBL] [Abstract][Full Text] [Related]
20. Bupropion increases striatal vesicular monoamine transport.
Rau KS; Birdsall E; Hanson JE; Johnson-Davis KL; Carroll FI; Wilkins DG; Gibb JW; Hanson GR; Fleckenstein AE
Neuropharmacology; 2005 Nov; 49(6):820-30. PubMed ID: 16005476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
